3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
37
Breast Neoplasms
23
Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Multiple Myeloma
14
Neoplasm Metastasis
13
Recurrence
10
Melanoma
10
Leukemia, Myeloid, Acute
10
Colorectal Neoplasms
10
Carcinoma, Renal Cell
10
Lymphoma, Non-Hodgkin
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Urinary Bladder Neoplasms
8
Lymphoma, Follicular
8
Thyroid Neoplasms
7
Hematologic Neoplasms
7
Stomach Neoplasms
6
Small Cell Lung Carcinoma
6
Sarcoma
6
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Mantle-Cell
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Lung Neoplasms
6
Head and Neck Neoplasms
6
Colonic Neoplasms
6
Uterine Cervical Neoplasms
5
Thyroid Cancer, Papillary
5
Interventions
darolutamide
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Metastatic Hormone-sensitive Prostate Cancer
×
1 year
×
Clear all
NCT02799602
2025-12-04
ARASENS
Bayer
Phase 3
Completed
1,306 enrolled
25 charts
2 FDA